{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"80.8","upperLimit":"95.0","value":"89.4"},{"groupId":"OG001","lowerLimit":"81.2","upperLimit":"94.1","value":"88.8"}]}],"title":"confirmed DCR by IRC"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"79.4","upperLimit":"94.2","value":"88.2"},{"groupId":"OG001","lowerLimit":"81.2","upperLimit":"94.1","value":"88.8"}]}],"title":"confirmed DCR by investigator"}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"107"}],"units":"Participants"}],"description":"To assess anti-tumor efficacy of Sunvozertinib using additional endpoints.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients were randomized at a 1:1 ratio to receive sunvozertinib 200 mg once daily continuously.","id":"OG000","title":"Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg"},{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients were randomized at a 1:1 ratio to receive sunvozertinib 300 mg once daily continuously.","id":"OG001","title":"Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Through the study completion, an average of around 1 year for part B","title":"Part B: DCR According to RECIST 1.1 Using Assessments Performed by an IRC; DCR Using Investigators Assessments According to RECIST 1.1","type":"SECONDARY","unitOfMeasure":"percentage of participants"}